Tag: Treatment failure

Approximately 30% of people with systemic lupus erythematosus are thought to be resistant to corticosteroids. A poor prednisone response occurs when a patient does not experience the expected therapeutic benefits from this anti-inflammatory medication, signaling a need for adjusted treatment strategies.

With approximately 39 million Americans living with migraine, a debilitating neurological disease, it's a common experience for acute treatments to sometimes fail. When a standard emergency room **migraine cocktail doesn't work**, it indicates a persistent and severe attack that requires an advanced, multi-pronged treatment strategy beyond the initial combination of medications.

Approximately one-third of individuals diagnosed with epilepsy will not achieve full seizure control with available medications. This challenge, known as drug-resistant epilepsy, highlights the fundamental question of **why do so many epilepsy drugs fail**, and it points toward the intricate biological and clinical factors at play.

According to a 2018 meta-analysis, primary resistance rates of *H. pylori* to levofloxacin were found to be above 15% in most WHO regions, with some areas having even higher levels. The question, "**Is H. pylori resistant to levofloxacin?**" is critically important for determining effective treatment strategies in an era of rising antibiotic resistance.

While intravenous (IV) iron infusions are highly effective for most people with severe iron deficiency, studies indicate that a significant number of patients may not achieve the desired hemoglobin increase on the first attempt. Therefore, **is it possible for an iron infusion to not work?** The answer is yes, though often for a discernible reason that requires further investigation.

It's estimated that more than 98% of people may have a genomic variant that could affect how they respond to commonly prescribed medications, according to the National Human Genome Research Institute. This genetic variation, among other factors, is a key reason many individuals ask, “Why am I resistant to medications?” when treatment fails to produce the expected results.

According to a 2021 study, more than 60% of people with multiple sclerosis (MS) using ocrelizumab (Ocrevus) experience a "wearing-off" phenomenon, where symptoms increase before the next scheduled infusion. This common occurrence often leads patients to question: does Ocrevus stop working?

According to the CDC, antibiotic resistance is a major threat to public health, making infections harder to treat. When faced with the question of **what if meropenem doesn't work?**, clinicians must investigate potential causes, from resistance mechanisms to patient-specific factors, to pivot toward effective alternative therapies.

For patients with autoimmune diseases, biologics can be life-changing, yet an estimated 30-40% of patients on biologics for conditions like rheumatoid arthritis stop treatment due to non-response or loss of efficacy. This can be a frustrating and confusing experience, leaving many to wonder, **why do biologics stop working?**

According to WebMD, about 30% to 40% of people with rheumatoid arthritis on a biologic stop using it, often because it stops working or causes intolerable side effects. Learning how do you know if your biologic is not working is key to getting the right treatment. This comprehensive guide details the signs of treatment failure and the steps to take next.